Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.50 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.45 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.45 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.45 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.45 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.45 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.45 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.45 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.45 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.45 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2124734 | 1.00 | CYP1A2 (0.50) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL3580142 | 1.00 | CYP1A2 (0.50) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL337707 | 0.98 | CYP1A2 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL561334 | 0.98 | CYP1A2 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL6740146 | 0.98 | CYP1A2 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28096244 | 0.96 | CYP1A2 (0.50) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL15888382 | 0.88 | GABRP (0.41) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL30439764 | 0.87 | ENPEP (0.43) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2218974 | 0.87 | ENPEP (0.43) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| Aminocaproic Acid SCHEMBL5709467 | 0.86 | LMNA (0.50) | CYP1A2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | claimed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | AMGEN INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4561968-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119841841-A | Cycloicaritin carbamate prodrug and salt thereof | 沈阳药科大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-4519278-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | Amgen Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119137136-A | Dual-residue extension peptide and preparation method thereof | 国立大学法人东海国立大学机构 | 2024-12-13 | — | — | CN | disclosed |
| US-20240293549-A1 | Conjugates And Conjugating Reagents | POLYTHERICS LIMITED (GB) | 2024-09-05 | — | — | US | disclosed |
| EP-2084161-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-08-05 | — | — | EP | disclosed |
| EP-1888618-A4 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LTD (NZ) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008056120-A1 | ADENINE DERIVATIVES AS INHIBITORS OF HSP90 FOR THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2008-05-15 | — | — | WO | disclosed |
| EP-1888618-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | Neuren Pharmaceuticals Limited (NZ) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
| EP-1151350-A4 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | UNIV CALIFORNIA (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1151350-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | The Regents of the University of California (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000031588-A1 | PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289842-A1 | Processes for Making NAG-25, a Carbohydrate Targeting Moiety, and its Intermediates | ENGASE, MAN2B2, GALNT2 | GRIN2D 4804/4885GRIN3B 3869/4885GRIN1 4008/4885 |
| US-20240293549-A1 | Conjugates And Conjugating Reagents | ANPEP, NGLY1, PCTP | GRIN2D 4651/4885GRIN3B 4175/4885GRIN1 4611/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | GRIN2D 1434/4885GRIN3B 966/4885GRIN1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.